My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 521 / DOI: 10.3332/ecancer.2015.521

Clinical Study

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent

Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has potent anti-angiogenic activity, and that it can inhibit the Hedgehog signalling pathway and may also induce autophagic growth arrest. The evidence for these anticancer effects, in vitro, in vivo, and clinical are summarised, and the putative mechanisms of their action outlined. Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. Given the evidence presented, a case is made that itraconazole warrants further clinical investigation as an anti-cancer agent. Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper.

Keywords: Drug repurposing, itraconazole, Hedgehog pathway inhibition, ReDO project

Loading Article Metrics ... Please wait

Related articles

Review: Targeted therapies and immunotherapy in non-small-cell lung cancer

Abstract | Full Article | PDF Published: 23 Jun 2016 / DOI: 10.3332/ecancer.2016.648

Case Report: Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)?

Abstract | Full Article | PDF Published: 07 Jun 2016 / DOI: 10.3332/ecancer.2016.646

Conference Report: Highlights from the Tenth European Breast Cancer Conference (EBCC10), Amsterdam, 9–11 March 2016

Abstract | Full Article | PDF Published: 03 Jun 2016 / DOI: 10.3332/ecancer.2016.644

Review: The steady progress of targeted therapies, promising advances for lung cancer

Abstract | Full Article | PDF Published: 28 Apr 2016 / DOI: 10.3332/ecancer.2016.638

Erratum: Erratum: Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year

Abstract | Full Article | PDF Published: 27 Apr 2016 / DOI: 10.3332/ecancer.2016.637



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence